United States: Lipitor MDL Court Grants Pfizer's Omnibus Summary Judgment Motion: No Evidence of Causation

Last Updated: January 12 2017
Article by Rachel B. Weil

For those of us who spend large chunks of our professional lives in mass tort MDLs, expressions like "settlement inventory" are ubiquitous. It is too easy to lose sight of the fact that these expressions put the rabbit in the hat, assuming that resourceful plaintiff lawyers will necessarily queue up for settlement payments at the end of the day and disregarding the fact that plaintiffs are supposed to be able to prove injury and causation before money changes hands. And so we were especially pleased to read last week's decisions in the Lipitor MDL, in which the cautious and relentlessly thorough MDL judge granted defendant Pfizer's omnibus summary judgment motion, dismissing all but a single newly-filed case, because the plaintiffs could not meet their burden of proving that Lipitor caused their diabetes. (There are two decisions relating to different dosages of Lipitor. You can read them here and here.)

The Lipitor MDL, created in February 2014, centralized cases in which female plaintiffs alleged that Lipitor – prescribed in dosages of 10 mg., 20 mg., 40 mg., and 80 mg. – caused them to develop Type 2 diabetes. In March and April of 2015, as trials of two bellwether cases approached, the plaintiffs served common expert disclosures of general causation experts, followed, in May and June, 2015, by specific causation expert disclosure in the two bellwether cases. After full expert discovery, Pfizer moved to exclude all of these experts. Ultimately, the court excluded the plaintiffs' expert testimony on general causation with respect to Lipitor dosages of 10, 20, and 40 mg. The court also excluded the testimony of the bellwether plaintiffs' specific causation experts, finding that the experts failed to rule out other possible causes of diabetes and relied impermissibly on temporal relationships, and granted summary judgment for Pfizer on the claims of both bellwether plaintiffs. (You can read our posts on these Daubert decisions here and here.)

However, the court left one general causation "window" open, based on one study finding that it was more likely than not that patients with certain characteristics who took 80 mg of Lipitor would not have developed diabetes in the absence of Lipitor. Thus, though neither of the bellwether plaintiffs had the requisite characteristics, it was possible that a plaintiff existed who took Lipitor at the 80 mg dosage and who could proffer a specific causation opinion that would survive Daubert.

But, in a January 2016 hearing, the plaintiffs' lead counsel confirmed that no plaintiff in the MDL satisfied these criteria. With the agreement of counsel for both sides, the court issued an order to show cause to see if any plaintiff could differentiate her case in a manner that would survive Daubert based on the decisions that had already been issued. If no such plaintiff came forward, the court would grant summary judgment in all of the cases pending in the MDL. The court's order required any plaintiff who "disputes the position taken by Plaintiffs' Lead Counsel and asserts that her case can survive summary judgment . . . [to] provide notice to the court within 15 days of this order and set forth with specificity how her case is distinguished from the Court's [earlier Daubert rulings]. The Court will then promptly set a schedule in each case for identifying expert witnesses."

Eleven months later, not a single plaintiff had come forward in response to the order to show cause. Instead, in opposition to Pfizer's summary judgment motion, the plaintiffs argued that it was "theoretically possible that some unidentified plaintiffs may have some unidentified circumstantial non-expert evidence of specific causation." In response, the court gave the plaintiffs yet another opportunity to come forward with any cases that could survive summary judgment. Again, not a single plaintiff came forward. Instead, the plaintiffs filed an omnibus response arguing that no plaintiff other than the two bellwether plaintiffs had had an opportunity to "hire experts" or "prepare expert reports."

Obviously, the court rejected this argument, given the multiple previous opportunities the plaintiffs had not seized. The court did, however, provide the plaintiffs with a final opportunity to defeat summary judgment by submitting non-expert evidence meeting their burden of proving causation. Two sets of plaintiffs came forward. One group of plaintiffs submitted nothing but their Plaintiff Fact Sheets and some of their medical records. They contended that they were diagnosed with diabetes after taking Lipitor and they lacked some risk factors for diabetes, though they had others. At oral argument, their lawyer stated that this "was the best thing [he] could come up with non-expert evidence" and reiterated that the plaintiffs were not diagnosed with diabetes until after they took Lipitor.

The second group of plaintiffs initially submitted no evidence at all. They argued that summary judgment was precluded by the their Fact Sheets and health histories, relevant general causation evidence, and the substantive state law applying to each of their claims. The court entered an order requiring these plaintiffs to submit any evidence they wanted the court to consider. In response, the plaintiffs "literally dumped boxes upon boxes of documents on the Court, with no discernment or suggestion as to which documents they claimed precluded summary judgment." And, the (saintly) court reviewed all of the documents, "almost all of which were completely irrelevant . . . [including] pictures from colonoscopies, EKGs, and pap smear results."

Dosages Less Than 80 mg.: General Causation

As explained, the court had previously excluded the testimony of the plaintiffs' general causation experts as to Lipitor dosages less than 80 mg. However, plaintiffs ingesting lower dosages of Lipitor argued that alleged admissions by Pfizer were sufficient to defeat summary judgment. The plaintiffs' primary piece of evidence was a one-sentence e-mail by a Pfizer vice president including the comment that "atorvastatin increases the risk of diabetes." The court held that the email was, "at best, evidence of an association, not causation. An association does not equal causation, and epidemiologists engage in a rigorous analysis of multiple factors to determine whether an association is causal." (Citations omitted). Moreover, "even if the one-sentence e-mail indicated that [the Pfizer vice president] thought Lipitor caused diabetes, the Court finds such an email could not replace expert testimony when expert testimony is required by substantive state law. (You can read about another decision applying this principle here.) A single statement by a single employee (even a Vice President) in a single email about a single study is not the type of clear declaration" that is sufficient to defeat summary judgment. Nor was NDA data allegedly demonstrating an association between Lipitor and increased blood glucose levels, or a statement on the Lipitor web site about reports of elevated blood sugar levels, or a Japanese label insert acknowledging a possible association. In sum, the plaintiffs had no evidence sufficient to create an issue of material fact on general causation as to 10, 20, and 40 mg. dosages of Lipitor, given the court's earlier exclusion of the plaintiffs' general causation expert's testimony as to these dosages, and plaintiffs taking these dosages of Lipitor could not survive summary judgment.

Specific Causation: Expert Testimony is Required

This left the question of whether an 80 mg. plaintiff could adduce sufficient specific causation evidence to capitalize on the open general causation "window."

In response to the plaintiffs' argument that some of the applicable states' laws would permit them to survive summary judgment on specific causation without expert testimony, the court stated, "While the specific language used by courts vary to some degree, all jurisdictions require expert testimony at least where the issues are medically complex and outside common knowledge and lay experience." (The court followed this statement with a fourteen-page string cite of precedents from all 50 states.) The court emphasized, “Here, expert testimony is certainly required. Diabetes is a complicated, progressive disease with a number of risk factors. Plaintiffs' general causation experts cannot even figure out how to determine whether an individual's diabetes was caused by Lipitor or other factors, and Plaintiffs' specific causation expert cannot determine which people in a room of 100 people or 10 people had ‘statin-induced’ diabetes as opposed to non-statin-induced diabetes . . . . If these experts cannot make this determination, it is certainly not within the common knowledge of a lay person. A jury's finding of causation in the absence of any expert testimony would be based on impermissible speculation or conjecture." (Citations omitted.)

Expert Testimony on General Causation Combined with Non-Expert Evidence

But the plaintiffs argued that, in some jurisdictions, a plaintiff can survive summary judgment with a combination of expert testimony that a substance is a possible cause of the plaintiff's injury and "non-expert" evidence. The court conceded that this statement is true "as far as it goes," but held, "Plaintiffs have pointed to no such probative, non-expert evidence here." The plaintiffs pointed to the fact that "numerous plaintiffs" had "no history of diabetes prior to their initial Lipitor exposures." The court responded (we love this), “This is undoubtedly true. It is impossible that Lipitor would have caused a Plaintiff's diabetes if she developed the disease prior to ever taking the drug. However, the converse of this statement is not true. Plaintiff may have developed diabetes after taking Lipitor, after having a grandchild, after tasting crème brulee for the first time, or after she turned 65. However the fact that Plaintiff developed diabetes after these events does not allow a reasonable jury to infer causation, without speculation and conjecture.” (Citations omitted.)

In short, the court concluded, while there are times when a temporal relationship can provide compelling evidence of causation, "such circumstances are not present here. Plaintiffs developed diabetes months or years after taking Lipitor and they had other substantial risk factors for the disease. The Court has already found that the temporal relationship at issue here is insufficient to form the basis of a reliable causation opinion under Daubert. . . . Therefore, it is necessarily insufficient to create an issue of fact as to causation." (Citations omitted).

Finally, the court rejected the argument that it had overstepped its role as an MDL court by addressing specific causation and that it should remand the cases to their transferor courts. The court held, "This Court is familiar with the science and issues present and can dispose of the issues far more quickly and efficiently than dozens of courts spread across the country."

And it did just that. For plaintiffs who ingested Lipitor dosages of less than 80 mg., the court held that the supposed 'admissions' did not create a genuine issue of material fact as to general causation, given the court's earlier exclusion of the plaintiffs' experts' general causation testimony related to these dosages. For all plaintiffs, the court held that temporal relationships could not create a genuine issue of material fact as to specific causation. And so, despite being given many more chances than they deserved, the Lipitor plaintiffs found themselves, quite properly, out of court. We hope that the judge's uncommon patience and precision ensures that these unassailable decisions will withstand appeal. We hope that you will read the decisions with appreciation, and we congratulate Pfizer on this hard-fought victory.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.